Page last updated: 2024-08-25

buparvaquone and Toxoplasmosis, Congenital

buparvaquone has been researched along with Toxoplasmosis, Congenital in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aguado-Martínez, A; Barrett, LK; Choi, R; Ferre, I; Hemphill, A; Hulverson, MA; Maly, DJ; McCloskey, MC; Moreno-Gonzalo, J; Müller, J; Ojo, KK; Ortega-Mora, LM; Van Voorhis, W	1

Other Studies

1 other study(ies) available for buparvaquone and Toxoplasmosis, Congenital

Article	Year
Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis. The Journal of antimicrobial chemotherapy, 2017, 08-01, Volume: 72, Issue:8 Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Female; Infectious Disease Transmission, Vertical; Male; Mice; Naphthalenes; Naphthoquinones; Piperidines; Pyrazoles; Toxoplasmosis, Animal; Toxoplasmosis, Congenital; Treatment Outcome	2017

Article

Year

Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis.

The Journal of antimicrobial chemotherapy, 2017, 08-01, Volume: 72, Issue:8

Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Female; Infectious Disease Transmission, Vertical; Male; Mice; Naphthalenes; Naphthoquinones; Piperidines; Pyrazoles; Toxoplasmosis, Animal; Toxoplasmosis, Congenital; Treatment Outcome

2017